Skip to main content

COVID 19 Updates from RheumNow

Boston and Wuhan Report Rheum COVID Patients at Risk for Respiratory Failure

Two current reports from Boston and Wuhan describe cohorts of COVID-19 (+) rheumatic disease patients who generally do well but appear to have a higher risk of pulmonary involvement.

Hydroxychloroquine Improves Survival in Lupus

Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients.

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

Again, Antimalarial Use Fails to Benefit COVID

Today Lancet reported the results of another retrospective trial showing that hydroxychloroquine or chloroquine, alone or with a macrolide antibioitic, offered no additional benefits to COVID-19 patients, but was associated with higher rates of mortality and arrhythmia.

Outcomes of Critically-Ill COVID Patients in NYC

Lancet has reported COVID outcomes from NewYork-Presbyterian hospitals in NYC during March 2020 showing high rates of hospitalization, ICU admission, mechanical ventilation and death. 

TNR - COVID-Rheumatology Registry & COVID in OZ

This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr.

Graduation

Congratulations! 

Years of training and work, all your efforts and overcoming hurdles have culminated in where you are today – on the verge of a new life, a new plan and possibly a new career.

High Dose Anakinra Effective in COVID-19

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs.

The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice.

RheumNow Podcast - COVID Kids and Men (5.15.20)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

CDC on Pediatric Multi-System Inflammatory Syndrome

The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.

Kids' COVID-Linked Ailment Is Not Your Typical Kawasaki Disease

As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.

Social

Awesome interview w/ @rheum_cat @JYazdanyMD @jeffsparks video link https://t.co/dVLayNchHT

TheDaoIndex @KDAO2011 ( View Tweet )

2 years 5 months ago
Please don’t miss MISC (pronounced Miss C)=multisystem inflammatory syndrome. Pediatric syndrome post #SARSCoV2 infection. May go w macrophage activation syndrome (MAS) w distinct proteomics signature. Potentially v poor outcomes. Need to dx and treat #ACR21 abst0961 @RheumNow https://t.co/uaBbUdg3lt
2 years 5 months ago
Dr. Petri on COVID19 infection vs vaccination on SLE activity: 💠Infection = NO increase SLE activity 💠Infection =⬇️ cutaneous activity 💠Infection = ⬆️anti-cardiolipin IgG/M 💠Vaccination: no increase in activity NOR aCL IgG/M https://t.co/fWbotSLS3o #ACR21 Abst#0858 @RheumNow

Pedro Castillo @_Castillo_Pedro ( View Tweet )

2 years 5 months ago
Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients Rubbert-Roth and colleagues found: - RA patients developed anti-S1 antibodies slower and lower compared to controls - Reduced titers among Abatacept & JAKi users #ACR21 @RheumNow https://t.co/sXW8d53O8m
Akhil Sood MD @AkhilSoodMD ( View Tweet )
2 years 5 months ago
#ACR21 #Abstr0866 Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts: Older age Male Areas outside Europe, 🇺🇸🇨🇦 Infection <June 2020 Any Corticosteroid dose Not on therapy On Rituximab Comorbidities ⬆️disease activity @RheumNow #ACRBest https://t.co/u0GF3aDsFA
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 5 months ago
#ACR21 #Abstr0858 Petri reported effect of #COVID and vaccination in #lupus cohort 💠No increase in activity post-infection 💠⬇️cutaneous activity 💠⬆️ aCL IgG and IgM post-infection, 💠No increase in SLE activity or aCL abs post-vaccination @RheumNow https://t.co/iAaIfzf33c https://t.co/hA6sk6icrs
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 5 months ago
Andy 0963 #ACR21 @RheumNow covid19 vaccine immunogenicity in rheum pts overall good at 71%, fairly dependent on Rx choice: rituximab 38% after 1g & only 7 % after 1gx2; abatacept IV 45%. Rest biologics >80%, ⬇️MTX &MMF. Low dose prednisone w/out biologics did not affect Ab+ rates https://t.co/TkCC1sgMHG
Olga Petryna @DrPetryna ( View Tweet )
2 years 5 months ago
Infx oral session 0964 Bitoun, et al. RTX lowers neutralizing Ab response compared to healthy controls, after COVID vaccination -- more supportive data https://t.co/6jvWHSjIgr #ACR21

Rheum Cat @rheum_cat ( View Tweet )

2 years 5 months ago
Outcomes of COVID-19 in Patients with Rheumatoid Arthritis. Dr. Akhil Sood ( @AkhilSoodMD) shares the studies presented #ACR21. https://t.co/yrs8N8XSiS https://t.co/EKHuTS5aDr
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21 👉🏼~1000 pts 👉🏼Severe outcomes esp in #GCA and #AAV 👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes @RheumNow https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL
Mrinalini Dey @DrMiniDey ( View Tweet )
2 years 5 months ago